{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:04:23Z","timestamp":1792609463505,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtha.2024.05.033","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T17:10:01Z","timestamp":1718385001000},"page":"2589-2600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in\u00a0vitro study"],"prefix":"10.1016","volume":"22","author":[{"given":"Jade","family":"Dubut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Goin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clo\u00e9","family":"Derray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Huguenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-8826","authenticated-orcid":false,"given":"Mathieu","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.05.033_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3324\/haematol.2020.248153","article-title":"Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy","volume":"106","author":"Nurden","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.033_bib2","first-page":"449","article-title":"Glanzmann thrombasthenia: perspectives from clinical practice on accurate diagnosis and optimal treatment strategies","volume":"12","author":"Mathews","year":"2021","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2024.05.033_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3324\/haematol.2018.214239","article-title":"ClinGen Platelet Disorder Variant Curation Expert Panel. Glanzmann thrombasthenia: genetic basis and clinical correlates","volume":"105","author":"Botero","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.033_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/humu.22776","article-title":"Expanding the mutation spectrum affecting \u03b1IIb\u03b23 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort","volume":"36","author":"Nurden","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jtha.2024.05.033_bib5","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-07-365635","article-title":"Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models","volume":"118","author":"Nurden","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/ejhg.2012.151","article-title":"Clinical utility gene card for: Glanzmann thrombasthenia","volume":"20","author":"Fiore","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jtha.2024.05.033_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MOH.0000000000000608","article-title":"Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions","volume":"27","author":"Lee","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtha.2024.05.033_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjh.15409","article-title":"How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults","volume":"182","author":"Grainger","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.033_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0038-1648233","article-title":"Alloimmunization in congenital deficiencies of platelet surface glycoproteins: focus on Glanzmann\u2019s thrombasthenia and Bernard-Soulier\u2019s syndrome","volume":"44","author":"Poon","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2018.05.002","article-title":"Acquired antibodies to \u03b1IIb\u03b23 in Glanzmann thrombasthenia: from transfusion and pregnancy to bone marrow transplants and beyond","author":"Nurden","year":"2018","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2024.05.033_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.15087","article-title":"Anti-\u03b1IIb \u03b23 immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations","volume":"181","author":"Fiore","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.033_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0040-1718373","article-title":"The use of recombinant activated factor VII in patients with Glanzmann\u2019s thrombasthenia","volume":"121","author":"Poon","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1046\/j.1538-7836.2003.00225.x","article-title":"Mechanism of action of recombinant factor VIIa","volume":"1","author":"Lisman","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.033_bib15","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2002-09-2761","article-title":"Recombinant factor VIIa enhances deposition of platelets with congenital or acquired \u03b1IIb\u03b23 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation","volume":"101","author":"Lisman","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2008-02-139113","article-title":"The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface","volume":"112","author":"Weeterings","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib17","first-page":"1031","article-title":"The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia","volume":"100","author":"Di Minno","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.033_bib18","first-page":"1038","article-title":"The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention","volume":"100","author":"Poon","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.033_bib19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1908993","article-title":"Current and future options of haemophilia A treatments","volume":"21","author":"Miesbach","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtha.2024.05.033_bib20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/jth.15697","article-title":"Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy","volume":"20","author":"Mast","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","article-title":"Concizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.05.033_bib22","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib24","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.033_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-0037-1613868","article-title":"The thrombogram: monitoring thrombin generation in platelet-rich plasma","volume":"83","author":"Hemker","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jclinpath-2018-205280","article-title":"Lysis Timer: a new sensitive tool to diagnose hyperfibrinolysis in liver transplantation","volume":"72","author":"Roullet","year":"2019","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtha.2024.05.033_bib28","first-page":"221","article-title":"Recent advances in the treatment of hemophilia: a review","volume":"15","author":"Marchesini","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.jtha.2024.05.033_bib29","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","article-title":"Targeting anticoagulant protein S to improve hemostasis in hemophilia","volume":"131","author":"Prince","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.05.033_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1538-7933.2004.00618.x","article-title":"Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics","volume":"2","author":"Vanschoonbeek","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI118859","article-title":"Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse\/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and \u201cclinical restenosis\u201d","volume":"98","author":"Reverter","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.05.033_bib33","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s00018-012-1033-2","article-title":"Key role of integrin \u03b1IIb\u03b23 signaling to Syk kinase in tissue factor-induced thrombin generation","volume":"69","author":"van der Meijden","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jtha.2024.05.033_bib34","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2017-03-773614","article-title":"Integrin \u03b1IIb\u03b23 outside-in signaling","volume":"130","author":"Durrant","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.lab.2004.02.001","article-title":"Glycoprotein IIb\/IIIa inhibitors increase COAT-platelet production in\u00a0vitro","volume":"143","author":"Hamilton","year":"2004","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jtha.2024.05.033_bib36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1538-7836.2009.03719.x","article-title":"RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation","volume":"8","author":"Jones","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/09537104.2011.642031","article-title":"The in\u00a0vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann\u2019s thrombasthenia","volume":"23","author":"Shenkman","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2024.05.033_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0038-1676348","article-title":"Low concentrations of recombinant factor VIIa may improve the impaired thrombin generation of Glanzmann thrombasthenia patients","volume":"119","author":"Levy-Mendelovich","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/blood-2017-05-785253","article-title":"Shear-induced integrin signaling in platelet phosphatidylserine exposure, microvesicle release, and coagulation","volume":"132","author":"Pang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay0203","article-title":"Impaired hemostatic activity of healthy transfused platelets in inherited and acquired platelet disorders: mechanisms and implications","volume":"11","author":"Lee","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2024.05.033_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/hae.13860","article-title":"Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and protein S in people with haemophilia","volume":"25","author":"Ellery","year":"2019","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.05.033_bib42","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.thromres.2012.02.023","article-title":"Platelet tissue factor pathway inhibitor modulates intravascular coagulation","volume":"129","author":"Maroney","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.033_bib43","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0038-1627453","article-title":"Suppressive role of tissue factor pathway inhibitor-\u03b1 in platelet-dependent fibrin formation under flow is restricted to low procoagulant strength","volume":"118","author":"Thomassen","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.033_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MBC.0000000000000870","article-title":"Clinico-hematological and thromboelastographic profiles in Glanzmann's thrombasthenia","volume":"31","author":"Ahammad","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.05.033_bib45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MBC.0000000000000532","article-title":"Perioperative ROTEM and ROTEMplatelet monitoring in a case of Glanzmann\u2019s thrombasthenia","volume":"28","author":"Grassetto","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.05.033_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood.V12.12.1125.1125","article-title":"Clot firmness","volume":"12","author":"Weiner","year":"1957","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/biomedicines9081064","article-title":"Clot retraction: cellular mechanisms and inhibitors, measuring methods, and clinical implications","volume":"9","author":"Jansen","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtha.2024.05.033_bib48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jtha.2022.10.005","article-title":"Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency","volume":"21","author":"Reitsma","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.05.033_bib49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139563","article-title":"Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events","volume":"136","author":"Seremetis","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.033_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/jth.15323","article-title":"Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in\u00a0vitro and ex\u00a0vivo analyses","volume":"19","author":"Kjalke","year":"2021","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:10:49Z","timestamp":1762549849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1538783624003568"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.033","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in\u00a0vitro study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}